OncoNephrology integrates oncology and nephrology and its importance has recently been recognized. The incidence of chronic kidney disease (CKD) in patients with cancer has been reported to be as high as 12-25%. In addition, patients with cancer are at a high risk of acute kidney injury (AKI), which can progress to CKD as a result of repeated AKI. Since impaired renal function in cancer patients reduces their ability to receive subsequent chemotherapy, decreases the rate of complete remission of cancer, and decreases life expectancy, it is important to correctly recognize and avoid the risk of kidney damage associated with cancer treatment to improve the prognosis of cancer patients. In addition, drug-induced kidney injury associated with the use of anticancer and molecular-targeted drugs occurs at various sites of injury and symptoms, making appropriate diagnosis and treatment critical. Therefore, in 2016, Japanese Society of Nephrology, Japanese Society of Clinical Oncology, Japanese Society of Medical Oncology, and the Japanese Society of Nephrology and Pharmacotherapy jointly developed the "Clinical Practice Guidelines for the Management of Kidney Injury During Anticancer Drug Therapy 2016.” This guideline clarified the evidence supporting clinical judgment and standard of care at the time. Six years have passed since its publication, during which time molecular-targeted drugs and immune checkpoint inhibitors have become widely used, and the renal disorders we encounter have changed significantly. Thus, we renewed the CQ, and largely addressed renal disorders caused by immune checkpoint inhibitors in the revised guidelines published in 2022. In this meeting, I would like to introduce the key points of the revision and discuss the updates to OncoNephrology.